|
Metastatic dermatofibrosarcoma protuberans (DFSP) and fibrosarcomatous DFSP (FS-DFSP): Sensitivity to imatinib (IM) and gene expression profile. |
| |
|
Research Funding - Novartis (Inst) |
| |
|
Research Funding - Novartis (Inst) |
| |
|
No Relationships to Disclose |
| |
|
Research Funding - Novartis (Inst) |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
Research Funding - Novartis (Inst) |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
Research Funding - Novartis (Inst) |
| |
|
|
Travel, Accommodations, Expenses - Novartis |
| |
|
|
Travel, Accommodations, Expenses - Novartis |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
Consulting or Advisory Role - Novartis |
| |
|
No Relationships to Disclose |
| |
|
|
Consulting or Advisory Role - Novartis |
Research Funding - Novartis (Inst) |
Travel, Accommodations, Expenses - Novartis |